No Data
No Data
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Its Pancreatic Cancer Treatment
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
Express News | VTv Therapeutics Inc - Net Loss Attributable to vTv Shareholders for Three Months Ended March 31, 2024, Was $4.9 Mln or $1.17 per Basic Share
Express News | VTv Therapeutics Q1 Operating Income USD -5.627 Million
Express News | VTv Therapeutics Q1 Operating Expenses USD 6.627 Million
vTv Therapeutics | 10-Q: Quarterly report
No Data